Kura Historical Balance Sheet

KURA Stock

USD 7.65 0.19 2.42%

Trend analysis of Kura Oncology balance sheet accounts such as Cash And Short Term Investments of 763.8 M provides information on Kura Oncology's total assets, liabilities, and equity, which is the actual value of Kura Oncology to its prevalent stockholders. By breaking down trends over time using Kura Oncology balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Kura Oncology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Kura Oncology is a good buy for the upcoming year.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.

About Kura Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Kura Oncology at a specified time, usually calculated after every quarter, six months, or one year. Kura Oncology Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Kura Oncology and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Kura currently owns. An asset can also be divided into two categories, current and non-current.

Kura Oncology Balance Sheet Chart

At present, Kura Oncology's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Stockholder Equity is expected to grow to about 434.3 M, whereas Net Debt is projected to grow to (197.5 M).

Total Assets Net Debt Cash And Short Term Investments Liabilities And Stockholders Equity Long Term Debt Total

Add Fundamental

Total Assets

Total assets refers to the total amount of Kura Oncology assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Kura Oncology books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Kura Oncology balance sheet. This account contains Kura Oncology investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Kura Oncology fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Liabilities And Stockholders Equity

The total of all liabilities and equity in the company, which should equal the company's total assets according to the accounting equation.

Most accounts from Kura Oncology's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Kura Oncology current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.At present, Kura Oncology's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Stockholder Equity is expected to grow to about 434.3 M, whereas Net Debt is projected to grow to (197.5 M).

	2024	2025 (projected)
Common Stock	8K	6.8K
Total Current Assets	744.8M	782.1M

Common Stock Total Current Assets

Kura Oncology balance sheet Correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Cash And Short Term Investments	Other Stockholder Equity	Total Current Assets	Common Stock	Short Long Term Debt Total	Total Current Liabilities	Other Assets	Common Stock Shares Outstanding	Non Current Liabilities Total	Total Liab	Short Term Debt	Other Current Liab	Accounts Payable	Common Stock Total Equity	Other Current Assets	Net Tangible Assets	Retained Earnings Total Equity	Capital Surpluse	Non Current Assets Total	Non Currrent Assets Other	Other Liab
Total Assets		0.12	-0.84	-0.92	0.87	1.0	0.95	1.0	-0.02	0.88	0.9	0.89	0.96	0.71	0.76	0.52	0.88	0.49	0.96	0.92	0.97	-0.9	0.97	0.94	0.84	-0.6
Total Stockholder Equity	0.12		-0.09	-0.31	0.12	0.11	0.19	0.12	0.0	0.23	0.47	-0.11	0.13	0.6	0.58	0.21	0.51	-0.26	0.02	0.4	-0.07	-0.04	0.06	0.24	0.49	-0.02
Net Debt	-0.84	-0.09		0.61	-1.0	-0.85	-0.72	-0.84	0.0	-0.67	-0.71	-0.89	-0.66	-0.61	-0.64	-0.53	-0.68	-0.31	-0.7	-0.75	-0.81	0.55	-0.72	-0.67	-0.51	0.36
Retained Earnings	-0.92	-0.31	0.61		-0.65	-0.91	-0.95	-0.92	0.01	-0.88	-0.93	-0.7	-0.97	-0.76	-0.81	-0.44	-0.93	-0.36	-0.91	-0.94	-0.85	0.95	-0.95	-0.96	-0.97	0.55
Cash	0.87	0.12	-1.0	-0.65		0.87	0.76	0.87	0.0	0.71	0.75	0.89	0.7	0.64	0.68	0.54	0.72	0.32	0.74	0.79	0.83	-0.59	0.75	0.71	0.56	-0.39
Cash And Short Term Investments	1.0	0.11	-0.85	-0.91	0.87		0.94	1.0	-0.02	0.88	0.9	0.89	0.95	0.7	0.76	0.52	0.87	0.5	0.96	0.91	0.97	-0.89	0.97	0.93	0.83	-0.6
Other Stockholder Equity	0.95	0.19	-0.72	-0.95	0.76	0.94		0.94	0.0	0.87	0.87	0.81	0.93	0.67	0.72	0.52	0.85	0.31	0.91	0.9	0.92	-0.93	0.97	0.98	0.88	-0.53
Total Current Assets	1.0	0.12	-0.84	-0.92	0.87	1.0	0.94		-0.02	0.88	0.9	0.89	0.96	0.71	0.76	0.52	0.88	0.5	0.96	0.91	0.97	-0.89	0.97	0.93	0.84	-0.6
Common Stock	-0.02	0.0	0.0	0.01	0.0	-0.02	0.0	-0.02		-0.01	0.01	-0.02	-0.08	0.01	0.01	0.03	-0.01	-0.1	-0.06	0.0	-0.03	0.02	-0.02	0.01	-0.01	0.21
Short Long Term Debt Total	0.88	0.23	-0.67	-0.88	0.71	0.88	0.87	0.88	-0.01		0.82	0.82	0.9	0.59	0.65	0.62	0.8	0.54	0.92	0.86	0.87	-0.88	0.9	0.87	0.84	-0.78
Total Current Liabilities	0.9	0.47	-0.71	-0.93	0.75	0.9	0.87	0.9	0.01	0.82		0.65	0.89	0.93	0.96	0.53	1.0	0.3	0.83	0.98	0.76	-0.79	0.86	0.87	0.93	-0.5
Other Assets	0.89	-0.11	-0.89	-0.7	0.89	0.89	0.81	0.89	-0.02	0.82	0.65		0.8	0.4	0.46	0.44	0.61	0.53	0.87	0.71	0.95	-0.76	0.86	0.8	0.59	-0.55
Common Stock Shares Outstanding	0.96	0.13	-0.66	-0.97	0.7	0.95	0.93	0.96	-0.08	0.9	0.89	0.8		0.67	0.72	0.43	0.87	0.55	0.98	0.89	0.93	-0.97	0.98	0.95	0.91	-0.66
Non Current Liabilities Total	0.71	0.6	-0.61	-0.76	0.64	0.7	0.67	0.71	0.01	0.59	0.93	0.4	0.67		1.0	0.51	0.94	0.05	0.58	0.89	0.5	-0.53	0.62	0.65	0.78	-0.29
Total Liab	0.76	0.58	-0.64	-0.81	0.68	0.76	0.72	0.76	0.01	0.65	0.96	0.46	0.72	1.0		0.52	0.96	0.11	0.65	0.92	0.57	-0.59	0.68	0.7	0.82	-0.34
Short Term Debt	0.52	0.21	-0.53	-0.44	0.54	0.52	0.52	0.52	0.03	0.62	0.53	0.44	0.43	0.51	0.52		0.51	0.15	0.45	0.55	0.45	-0.37	0.46	0.43	0.4	-0.64
Other Current Liab	0.88	0.51	-0.68	-0.93	0.72	0.87	0.85	0.88	-0.01	0.8	1.0	0.61	0.87	0.94	0.96	0.51		0.26	0.8	0.97	0.73	-0.77	0.83	0.86	0.93	-0.47
Accounts Payable	0.49	-0.26	-0.31	-0.36	0.32	0.5	0.31	0.5	-0.1	0.54	0.3	0.53	0.55	0.05	0.11	0.15	0.26		0.64	0.26	0.58	-0.48	0.51	0.38	0.33	-0.76
Common Stock Total Equity	0.96	0.02	-0.7	-0.91	0.74	0.96	0.91	0.96	-0.06	0.92	0.83	0.87	0.98	0.58	0.65	0.45	0.8	0.64		0.85	0.96	-0.95	0.98	0.92	0.84	-0.72
Other Current Assets	0.92	0.4	-0.75	-0.94	0.79	0.91	0.9	0.91	0.0	0.86	0.98	0.71	0.89	0.89	0.92	0.55	0.97	0.26	0.85		0.8	-0.82	0.88	0.88	0.91	-0.49
Net Tangible Assets	0.97	-0.07	-0.81	-0.85	0.83	0.97	0.92	0.97	-0.03	0.87	0.76	0.95	0.93	0.5	0.57	0.45	0.73	0.58	0.96	0.8		-0.9	0.97	0.91	0.75	-0.62
Retained Earnings Total Equity	-0.9	-0.04	0.55	0.95	-0.59	-0.89	-0.93	-0.89	0.02	-0.88	-0.79	-0.76	-0.97	-0.53	-0.59	-0.37	-0.77	-0.48	-0.95	-0.82	-0.9		-0.97	-0.95	-0.88	0.61
Capital Surpluse	0.97	0.06	-0.72	-0.95	0.75	0.97	0.97	0.97	-0.02	0.9	0.86	0.86	0.98	0.62	0.68	0.46	0.83	0.51	0.98	0.88	0.97	-0.97		0.97	0.87	-0.62
Non Current Assets Total	0.94	0.24	-0.67	-0.96	0.71	0.93	0.98	0.93	0.01	0.87	0.87	0.8	0.95	0.65	0.7	0.43	0.86	0.38	0.92	0.88	0.91	-0.95	0.97		0.93	-0.53
Non Currrent Assets Other	0.84	0.49	-0.51	-0.97	0.56	0.83	0.88	0.84	-0.01	0.84	0.93	0.59	0.91	0.78	0.82	0.4	0.93	0.33	0.84	0.91	0.75	-0.88	0.87	0.93		-0.53
Other Liab	-0.6	-0.02	0.36	0.55	-0.39	-0.6	-0.53	-0.6	0.21	-0.78	-0.5	-0.55	-0.66	-0.29	-0.34	-0.64	-0.47	-0.76	-0.72	-0.49	-0.62	0.61	-0.62	-0.53	-0.53

Click cells to compare fundamentals

Kura Oncology Account Relationship Matchups

Kura Oncology balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	647.2M	534.1M	456.3M	448.9M	760.2M	798.2M
Total Stockholder Equity	(302.5M)	(433.0M)	(568.8M)	397.3M	413.6M	434.3M
Net Debt	(310.5M)	(83.8M)	(37.8M)	(20.1M)	(207.9M)	(197.5M)
Retained Earnings	(302.5M)	(433.0M)	(568.8M)	(721.4M)	(895.4M)	(850.7M)
Cash	325.5M	90.7M	51.8M	37.3M	224.5M	235.7M
Cash And Short Term Investments	633.3M	518.0M	438.0M	424.0M	727.4M	763.8M
Liabilities And Stockholders Equity	(266.2M)	(405.5M)	(532.8M)	448.9M	760.2M	798.2M
Other Stockholder Equity	913.4M	941.4M	997.1M	1.1B	1.3B	1.4B
Total Current Assets	637.3M	522.3M	446.4M	432.5M	744.8M	782.1M
Short Long Term Debt Total	15.0M	6.9M	14.0M	17.2M	16.6M	17.4M
Total Current Liabilities	26.0M	22.5M	24.1M	35.3M	78.7M	82.6M
Other Assets	2.1M	7.9M	3.5M	3.5M	4.0M	4.2M
Common Stock Shares Outstanding	53.1M	66.4M	67.0M	73.2M	86.2M	90.5M
Non Current Liabilities Total	10.3M	5.0M	12.0M	16.4M	267.8M	281.2M
Total Liab	36.3M	27.4M	36.0M	51.7M	346.5M	363.8M
Short Term Debt	5.1M	2.3M	4.6M	1.5M	6.4M	6.7M
Other Current Liab	18.2M	17.0M	17.9M	31.5M	68.8M	72.3M
Accounts Payable	2.8M	3.2M	1.5M	2.3M	1.5M	1.9M
Other Current Assets	7.9M	2.9M	8.4M	8.5M	17.4M	18.3M
Net Tangible Assets	218.8M	610.9M	506.6M	420.3M	483.3M	507.5M
Retained Earnings Total Equity	(212.9M)	(302.5M)	(433.0M)	(568.8M)	(511.9M)	(486.3M)
Capital Surpluse	431.3M	913.4M	941.4M	997.1M	1.1B	1.2B
Non Current Assets Total	9.9M	11.8M	9.9M	16.5M	15.3M	16.1M
Non Currrent Assets Other	1.4M	3.3M	3.3M	7.6M	7.8M	8.2M
Other Liab	377K	395K	375K	265K	238.5K	324.6K
Property Plant And Equipment Net	8.4M	8.2M	6.4M	8.9M	7.5M	4.3M
Long Term Debt	7.3M	4.3M	9.2M	9.3M	6.9M	7.2M
Short Term Investments	307.8M	427.3M	386.2M	386.6M	502.9M	266.5M
Property Plant And Equipment Gross	8.4M	9.1M	8.0M	11.3M	10.8M	11.3M
Accumulated Other Comprehensive Income	46K	(1.8M)	(8.0M)	(1.3M)	764K	802.2K
Non Current Liabilities Other	6.0M	5.0M	265K	705K	1.8M	1.7M
Long Term Debt Total	7.5M	7.3M	4.3M	9.2M	10.5M	7.5M
Net Invested Capital	618.2M	506.6M	429.4M	406.6M	423.2M	394.0M
Net Working Capital	611.3M	499.8M	422.4M	397.2M	666.1M	422.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Kura Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kura Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kura Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kura Oncology Stock:

How To Invest In Kura

Details

Is Kura Stock a good investment?

Details

What is Kura Oncology's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.

You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.02)

Revenue Per Share

0.625

Return On Assets

(0.20)

Return On Equity

(0.43)

The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Kura Historical Balance Sheet

About Kura Balance Sheet Analysis

Kura Oncology Balance Sheet Chart

Total Assets

Net Debt

Cash And Short Term Investments

Liabilities And Stockholders Equity

Kura Oncology balance sheet Correlations

Kura Oncology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Kura Oncology balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Other Current Liab	+ 1.0	Total Current Liabilities
Total Liab	+ 1.0	Non Current Liabilities Total
Non Current Assets Total	+ 0.98	Other Stockholder Equity

Cash	- 1.0	Net Debt
Capital Surpluse	- 0.97	Retained Earnings Total Equity
Retained Earnings Total Equity	- 0.97	Common Stock Shares Outstanding
Non Currrent Assets Other	- 0.97	Retained Earnings
Common Stock Shares Outstanding	- 0.97	Retained Earnings
Non Current Assets Total	- 0.96	Retained Earnings